Federal Judge Orders FDA to Reconsider Mifepristone Restrictions Amid Abortion Access Debate
A federal judge in Virginia has ruled that the restrictions imposed by the Food and Drug Administration (FDA) on the abortion medication mifepristone are arbitrary and capricious. Judge Robert S. Ballou ordered the FDA to reconsider these restrictions, which have been challenged as barriers to abortion access. The case, Whole Woman’s Health Alliance v. FDA, was initiated by the Center for Reproductive Rights on behalf of abortion providers in Virginia, Kansas, and Montana. The FDA's current restrictions include requirements for special registration and certification for providers and pharmacies, as well as additional paperwork for patients. The ruling comes as the FDA, without a permanent commissioner, is reviewing abortion pill regulations under pressure from conservative lawmakers. Mifepristone, which accounts for nearly two-thirds of all abortions in the U.S., has been deemed safe and effective by decades of studies. 
